Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes the company as currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event ending the wait. Let's analyze the transcript. Key points from the call: - Rob Fried: "we're at an inflection point for this company with litigation largely behind us. We are already devoting more resources, both human and financial, to building our Tru Niagen brand and developing our science and furthering our relationships with global partners." This is about investing in brand and science, but not necessarily a defined waiting period. - They launched TV advertising, new commercial in March. They are testing and scaling campaigns. This is marketing investment, but it's ongoing and not a specific waiting period for a single event. - They mention new product launch this year: "we're launching a new Tru Niagen product this year to broaden our customer base by targeting another important benefit area. I'm excited to share more once it's in the market." This is a product launch, but they don't give a specific date, and it's not clear that they are currently paying for something with no return yet. They are developing it, but it's not described as a major cost burden. - They mention partnerships: Sinopharm, H&H, Designs for Health. They are working on commercial plans, but not yet contributing significantly. However, they say "All of our new partnerships in various stages of product development, but we expect them to contribute to increased sales in 2022." This is future contribution, but not a defined waiting period with a specific near-dated event. - They mention R&D investment: "R&D will be up approximately $2 million as we invest in new NAD precursor development related to our recently granted patent among others." This is investment, but not a waiting period. - They mention legal expense reduction, but that's behind them. The question asks: Does management describe the company as CURRENTLY LIVING THROUGH A DEFINED WAITING PERIOD IT IS PAYING FOR OUT OF ITS OWN POCKET? That is, real ongoing cash or earnings cost for something whose benefit has not arrived yet, and the end of that waiting period is a specific, near-dated event.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.